Looks like you’re on the UK site. Choose another location to see content specific to your location
Qiagen licenses biomarkers for use in immuno-oncology diagnostics
Qiagen has received a worldwide licence for a number of biomarkers that can be used to identify patients most likely to benefit from immuno-oncology drugs.
The deal with Johns Hopkins University will give Qiagen rights to genetic biomarkers to assess microsatellite instability and mismatch repair in all sample and cell types, allowing the firm to commercialise molecular testing solutions to assess these statuses.
Along with tumour mutation burden, these metrics are important in identifying cancer patients who are genetically predisposed to respond well to certain types of immuno-oncology therapy, which target the body's immune system to help fight cancer.
Jonathan Arnold, vice-president and head of precision diagnostics at Qiagen, said: "Working closely with our partners in the pharmaceutical industry, we intend to commercialise companion diagnostics and complementary diagnostics that will further strengthen Qiagen's global leadership in this area."
The company currently offers a portfolio of personalised healthcare assays covering about 30 biomarkers, and also has more than 20 master collaboration agreements with leading pharmaceutical companies to develop companion diagnostic assays to guide the use of therapies for cancers and other diseases.
With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard